Zydus Lifesciences shares were last seen 0.41 per cent up at Rs 891.55. At this price, the stock has slipped 8.43 per cent in ...

to manufacture Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg (Niaspan Extended-Release Tablets, 500 mg, 750 mg, and 1,000 mg). Niacin is indicated to reduce elevated total ...

to manufacture Niacin Extended-Release Tablets USP, 500 mg , 750 mg, and 1,000 mg. The approved medication is indicated for the treatment of patients with primary hyperlipidemia and mixed dyslipidemia ...

The pharmaceutical company has been awarded the final approval for the manufacture of Niacin Extended-Release Tablets USP in the dosages 500 mg, 750 mg, and 1,000 mg by the USFDA. The US health ...

Two persons were arrested with 500 gm heroin in Bathinda. The SP said the accused, Sukha, had earlier been caught with 7 gm heroin in Sirsa district of Haryana.

Zydus Lifesciences Ltd on Wednesday said it has received final approval from the US health regulator to manufacture the ...

Grünenthal is paying up to €500 million ($501 million) for rights to Nebido (testosterone undecanoate), which is sold in around 80 countries worldwide for testosterone deficiency and made sales ...

FRIDAY, May 2, 2025 (HealthDay News) -- A common diabetes drug can be repurposed to help overweight and obese people with knee arthritis, a new study says. Metformin reduced knee arthritis pain during ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.